Universität zu Köln

Fuerstenau, Moritz, Hallek, Michael and Eichhorst, Barbara (2019). Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica, 104 (11). S. 2144 - 2155. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Full text not available from this repository.

Abstract

Chemoimmunotherapy has been the standard of care for patients with chronic lymphocytic leukemia for a long time. However, over the last few years, novel agents have produced unprecedented outcomes in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. With the advent of these targeted agents, treatment options have diversified very considerably and new questions have emerged. For example, it is unclear whether these novel agents should be used as sequential monotherapies until disease progression or whether they should preferably be combined in time-limited treatment regimens aimed at achieving deep and durable remissions. While both approaches yield high response rates and long progression-free and overall survival, it remains challenging to identify patients individually for the optimal concept. This review provides guidance in this decision process by presenting evidence on sequential and combined use of novel agents and discussing the advantages and drawbacks of these two approaches.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Fuerstenau, Moritz UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-130121
DOI:	10.3324/haematol.2018.208603
Journal or Publication Title:	Haematologica
Volume:	104
Number:	11
Page Range:	S. 2144 - 2155
Date:	2019
Publisher:	FERRATA STORTI FOUNDATION
Place of Publication:	PAVIA
ISSN:	0390-6078
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; RICHTER TRANSFORMATION; PROGRESSION-FREE; DOSE-ESCALATION; FREE SURVIVAL; IBRUTINIB; RITUXIMAB; IDELALISIB; VENETOCLAX; CLL Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13012